Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.

Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Gilead Sciences (GILD – Research Report). The associated price ...

There was some good news in the clinical sphere for Gilead Sciences (NASDAQ: GILD) on Thursday, and this drove its stock ...

In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.

Gilead Sciences (GILD) reported the results of an interim analysis from a second Phase 3 clinical trial investigating the use of the ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Gilead Sciences Inc.’s twice-yearly HIV prevention shot prevented almost all HIV cases in a large trial in men and transgender people, a result that will allow the company to file for approval by end ...

Gilead's news was that its second phase 3 trial ... drug reduced new infections with the disease by 96% when compared to background HIV incidence. Lenacapavir, which is only administered twice ...